The decades-long trend of rising drug prices, described by Eroom’s Law, is in part a result of regulatory inefficiencies.
Scientists have slammed the new guidance which allows for the interchange of vaccines, if the second dose of the vaccine originally received is not available, saying officials have abandoned science and are just trying to 'guess their way out of a mess'
Tests have shown that this new gel, which is less than half-inch thick, can provide cooling of more than sever degrees Celsius for five times longer than hydrogel alone.
India pledges $15-mn at virtual global vaccine summit; funds to be used for immunisation programmes across the world
Prime Minister Narendra Modi on Thursday pledged $15-million as India's contribution to the vaccines alliance GAVI at the Global Vaccine Summit hosted by the UK
Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down
Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses
Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh
Coronavirus outbreak highlighted vulnerabilities in medical manufacturing supply chain: Fitch Solutions
With pharmaceutical supply chains under immense pressure due to COVID-19, China's role as a global ingredient producer has come under scrutiny, Fitch Solutions has said
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh
Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur
Coronavirus Outbreak: The story of a premier US pharma company that became a COVID-19 'super spreader'
On the first Monday in March, Michel Vounatsos, chief executive of the drug company Biogen, appeared in good spirits. The company’s new Alzheimer’s drug was showing promise after years of setbacks. Revenues had never been higher
Tussle over hydroxychloroquine puts India's neighbourhood first policy at odds with efforts to appease Trump
On Tuesday, India lifted an export ban on 24 active pharmaceutical ingredients, believed to be critical in the battle against coronavirus
Coronavirus may impact India's March quarter GDP growth by 0.20% after epidemic hits imports from China for crucial sectors: Report
The brokerage cut its fiscal 2020-21 real GDP growth estimate marginally to 5.6% as against the previous estimate of 5.7%, but added that there will be a recovery in the next financial year.
Govt working on incentives to promote industrial development in J&K region: Commerce Minister Piyush Goyal
The government is working on several incentives and steps to promote industrial development in the Jammu and Kashmir region, Commerce and Industry Minister Piyush Goyal said on Wednesday
The Jan Aushadhi scheme, under which the government provides quality medicines at affordable rates may disrupt around 20 percent of Indian pharmaceutical market sales, says a report
Exports up 2.44% to $26.67 bn in February on higher shipments in pharma, engineering sectors; trade deficit narrows
Imports declined by 5.4 percent to $36.26 billion in the last month, narrowing the trade deficit to $9.6 billion. The gap between imports and exports was $12.3 billion in February 2018.
The plant offers many benefits over today's painkillers, including not being addictive: Study.
"The first quarter of FY2019 has been subdued, primarily on account of the US and Japan," Lupin Ltd Managing Director Nilesh Gupta said in a statement.
India's trade deficit widens to more than five-year high of $16.6 bn; imports soar by 21.31% to $44.3 bn
The trade deficit in June 2018 is the highest since November 2014 when the gap was $16.86 billion. The deficit in June 2017 stood at $12.96 billion
Currently prescribed drugs to Alzheimer's patients offer symptomatic relief, but do not slow, stop or reverse the damage done.
Lupin currently has 162 abbreviated new drug applications (ANDAs) pending approval with the US Food and Drug Administration (USFDA)